82_FR_49587 82 FR 49382 - Deciding When To Submit a 510(k) for a Software Change to an Existing Device; Guidance for Industry and Food and Drug Administration Staff; Availability

82 FR 49382 - Deciding When To Submit a 510(k) for a Software Change to an Existing Device; Guidance for Industry and Food and Drug Administration Staff; Availability

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 82, Issue 205 (October 25, 2017)

Page Range49382-49384
FR Document2017-23196

The Food and Drug Administration (FDA or Agency) is announcing the availability of the guidance entitled ``Deciding When to Submit a 510(k) for a Software Change to an Existing Device.'' FDA is issuing this final guidance document to clarify when a software change in a legally marketed medical device would require that a manufacturer submit a premarket notification (510(k)) to FDA. FDA is correcting an error in the docket number assigned to the ``Deciding When to Submit a 510(k) for a Software Change to an Existing Device'' notice of availability when it published in the Federal Register (81 FR 52441, August 8, 2016). The docket number currently is FDA-2011-D-0453. FDA is changing the docket number to FDA-2016-D-2021. This action is administrative in nature and is being taken to avoid any potential confusion in the docket.

Federal Register, Volume 82 Issue 205 (Wednesday, October 25, 2017)
[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Pages 49382-49384]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-23196]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-2021]


Deciding When To Submit a 510(k) for a Software Change to an 
Existing Device; Guidance for Industry and Food and Drug Administration 
Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of the guidance entitled ``Deciding When to Submit a 
510(k) for a Software Change

[[Page 49383]]

to an Existing Device.'' FDA is issuing this final guidance document to 
clarify when a software change in a legally marketed medical device 
would require that a manufacturer submit a premarket notification 
(510(k)) to FDA. FDA is correcting an error in the docket number 
assigned to the ``Deciding When to Submit a 510(k) for a Software 
Change to an Existing Device'' notice of availability when it published 
in the Federal Register (81 FR 52441, August 8, 2016). The docket 
number currently is FDA-2011-D-0453. FDA is changing the docket number 
to FDA-2016-D-2021. This action is administrative in nature and is 
being taken to avoid any potential confusion in the docket.

DATES: The announcement of the guidance is published in the Federal 
Register on October 25, 2017.

ADDRESSES: You may submit either electronic or written comments on 
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2016-D-2021 for ``Deciding When to Submit a 510(k) for a Software 
Change to an Existing Device.'' Received comments will be placed in the 
docket and, except for those submitted as ``Confidential Submissions,'' 
publicly viewable at https://www.regulations.gov or at the Dockets 
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    An electronic copy of the guidance document is available for 
download from the internet. See the SUPPLEMENTARY INFORMATION section 
for information on electronic access to the guidance. Submit written 
requests for a single hard copy of the guidance document entitled 
``Deciding When to Submit a 510(k) for a Software Change to an Existing 
Device'' to the Office of the Center Director, Guidance and Policy 
Development, Center for Devices and Radiological Health, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver 
Spring, MD 20993-0002, or the Office of Communication, Outreach, and 
Development, Center for Biologics Evaluation and Research, Food and 
Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, 
Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to 
assist that office in processing your request.

FOR FURTHER INFORMATION CONTACT: Linda Ricci, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 66, Rm. G634, Silver Spring, MD 20993-0002, 301-796-6325, 
[email protected]; and Stephen Ripley, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.

SUPPLEMENTARY INFORMATION:

I. Background

    A 510(k) is required when a legally marketed device subject to 
510(k) requirements is about to be significantly changed or modified in 
design, components, method of manufacture, or intended use. Significant 
changes or modifications are those that could significantly affect the 
safety or effectiveness of the device, or major changes or 
modifications in the intended use of the device (Sec.  807.81(a)(3) (21 
CFR 807.81(a)(3)). This guidance will aid manufacturers of medical 
devices who intend to make a software modification to a 510(k)-cleared 
device or other device subject to 510(k) requirements, such as a 
preamendments device or a device that was granted marketing 
authorization via the De Novo classification process under section 
513(f)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) 
(21 U.S.C. 360c(f)(2)) (also referred to together as ``existing 
devices''), during the process of deciding whether the software 
modification exceeds the regulatory threshold of Sec.  807.81(a)(3) for 
submission and clearance of a new 510(k).

[[Page 49384]]

    This guidance specifically addresses software design and technology 
modifications, including firmware. This guidance does not apply to 
software for which the Agency has stated in guidance that it does not 
intend to enforce compliance with applicable regulatory controls (e.g., 
``Mobile Medical Applications: Guidance for Industry and FDA Staff,'' 
issued February 9, 2015, available on the internet at https://www.fda.gov/downloads/medicaldevices/.../ucm263366.pdf) and software 
that does not meet the definition of a medical device at section 201(h) 
of the FD&C Act (21 U.S.C. 321(h)).
    In the Federal Register on August 8, 2016, FDA announced the 
availability of the draft guidance and interested parties were 
requested to comment by November 7, 2016. FDA considered comments 
received on the draft guidance and revised the guidance as appropriate.
    This guidance is not intended to implement significant policy 
changes to FDA's current thinking on when submission of a new 510(k) is 
required for a software change to an existing device. Rather, the 
intent of this guidance is to enhance the predictability, consistency, 
and transparency of the ``when to submit'' decision-making process by 
providing a least burdensome approach, and describing in greater detail 
the regulatory framework, policies, and practices underlying such a 
decision, specifically as it relates to software changes. The 
recommendations discussed in this guidance for evaluating when a 
software change to an existing device would trigger the requirement 
that a manufacturer submit a new 510(k) to the Agency are consistent 
with the least burdensome principles (Refs. 1 and 2). This guidance 
applies the least burdensome principles, in part, by reliance on risk 
management and the quality system regulation (21 CFR part 820) to 
determine whether submission of a new 510(k) is required for a software 
change to an existing device.
    Elsewhere in this issue of the Federal Register, FDA is announcing 
the availability of the guidance document entitled ``Deciding When to 
Submit a 510(k) for a Change to an Existing Device,'' to aid 
manufacturers of medical devices who intend to make non-software 
changes to an existing device during the process of deciding whether 
the modification exceeds the regulatory threshold of Sec.  
[thinsp]807.81(a)(3) for submission and clearance of a new 510(k).

II. Significance of Guidance

    This guidance is being issued consistent with FDA's good guidance 
practices regulation (21 CFR 10.115). The guidance represents the 
current thinking of FDA on ``Deciding When to Submit a 510(k) for a 
Software Change to an Existing Device.'' It does not establish any 
rights for any person and is not binding on FDA or the public. You can 
use an alternative approach if it satisfies the requirements of the 
applicable statutes and regulations. This guidance is not subject to 
Executive Order 12866.

III. Electronic Access

    Persons interested in obtaining a copy of the guidance may do so by 
downloading an electronic copy from the internet. A search capability 
for all Center for Devices and Radiological Health guidance documents 
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance 
documents are also available at https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or https://www.regulations.gov. Persons unable to 
download an electronic copy of ``Deciding When to Submit a 510(k) for a 
Software Change to an Existing Device'' may send an email request to 
[email protected] to receive an electronic copy of the 
document. Please use the document number 1500055 to identify the 
guidance you are requesting.

IV. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of 
information found in FDA regulations. These collections of information 
are subject to review by the Office of Management and Budget (OMB) 
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The 
collections of information in 21 CFR part 820 are approved under OMB 
control number 0910-0073; the collections of information in 21 CFR part 
807, subpart E are approved under OMB control number 0910-0120; the 
collections of information in 21 CFR part 803 are approved under OMB 
control number 0910-0437; and the collections of information in 21 CFR 
parts 801 are approved under OMB control number 0910-0485.

V. References

    The following references are on display in the Dockets Management 
Staff (see ADDRESSES) and are available for viewing by interested 
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also 
available electronically at https://www.regulations.gov. FDA has 
verified the Web site addresses, as of the date this document publishes 
in the Federal Register, but Web sites are subject to change over time.

1. ``The Least Burdensome Provisions of the FDA Modernization Act of 
1997: Concept and Principles,'' dated October 4, 2002, available at: 
https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085999.pdf.
2. ``Suggested Format for Developing and Responding to Deficiencies 
in Accordance with the Least Burdensome Provisions of FDAMA,'' dated 
November 2, 2000, available at: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073680.pdf.

    Dated: October 20, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-23196 Filed 10-24-17; 8:45 am]
BILLING CODE 4164-01-P



                                                49382                     Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices

                                                Practice Inspection Mutual Recognition                  NADA application cohort with a 180-                   adjustment up to the amount of excess
                                                Agreement. All other commitments                        day review timeframe.                                 collections in the second preceding
                                                related to pre-approval inspections will                   The Agency will review and act on 90               fiscal year. The first fiscal year this
                                                remain the same as ADUFA III.                           percent of resubmissions of previously                provision could be applied while setting
                                                   The Agency will review and act on 90                 completed Environmental Impact                        fees is FY 2021. Likewise, the proposal
                                                percent of qualifying Animal Drug                       technical sections within 60 days after               also provides authority to the Secretary
                                                Availability Act (ADAA) combination                     the submission date where:                            to reduce an increase in fees to recover
                                                medicated feed applications within 60                      • A categorical exclusion was issued;              a shortfall in collections in a preceding
                                                days after the submission date when all                    • All other technical sections have                year (after 2018) by any remaining prior
                                                of the following conditions are met:                    been submitted; and                                   year excess collections not already
                                                   • Basic regulatory requirements for an                  • Information contained in the other               applied for purposes of reducing fee
                                                ADAA combination medicated feed                         technical sections reveals a change in                increases.
                                                application has been met as outlined in                 the conditions of use of the previously
                                                                                                        issued categorical exclusion.                         D. Impact of ADUFA IV Enhancements
                                                21 CFR 514.4(c)(2)(ii).
                                                                                                                                                              on User Fee Revenue
                                                   • A presubmission conference has                        The Agency will conduct 90 percent
                                                been conducted and either:                              of qualifying presubmission conferences                  The FY 2019 baseline for ADUFA IV
                                                   Æ No data (no tissue residue non-                    within a 60-day timeframe when all of                 is $30,331,240, which includes a
                                                interference study is required) are                     the following conditions are met:                     $400,000 one-time cost for information
                                                needed and this agreement is                               • All background materials, including              technology enhancement. For each year
                                                documented in the memorandum of                         presentations, have been submitted, and               from FY 2020 through FY 2023, the
                                                conference for the presubmission                           • A complete agenda has been agreed                annual statutory revenue amounts
                                                conference; or                                          upon by the Agency and the sponsor.                   established in section 741(b) of the
                                                   Æ A justification for not conducting a                  A sponsor and the Agency can                       FD&C Act (21 U.S.C. 379j–21(b)) will be
                                                tissue residue non-interference study                   mutually agree to exclude a particular                further adjusted by the inflation
                                                has been submitted, reviewed, and                       presubmission conference from this                    adjuster, the workload adjuster, if
                                                found acceptable under an                               performance goal. If a sponsor accepts a              applicable, and will include $900,000
                                                investigational new animal drug (INAD),                 date beyond the 60-day timeframe for                  per year for tissue method trials.
                                                prior to the submission of the ADAA                     their scheduling purposes or is unable                   The total 5-year revenue planned for
                                                combination medicated feed                              to meet with the Agency on Agency                     ADUFA I was $47,000,000. The total 5-
                                                application; or                                         available dates, the submission will be               year revenue planned for ADUFA II was
                                                   Æ A tissue residue non-interference                  excluded from the presubmission                       $98,000,000. The total 5-year revenue
                                                study has been submitted, reviewed,                     conference cohort.                                    planned for ADUFA III was
                                                and found acceptable under an INAD,                        The Agency will commence 90                        $114,000,000. It is estimated that the
                                                prior to the submission of the ADAA                     percent of tissue residue method                      total 5-year revenue for ADUFA IV will
                                                combination medicated feed                              demonstrations within 120 days of                     be $150,000,000.
                                                application.                                            completion of the 3-hour meeting                         The fee revenue distribution in
                                                   • No effectiveness or target animal                  process or within 200 days from the                   ADUFA IV will remain the same as
                                                safety data are required.                               receipt of a submission that supports a               ADUFA III: 20 percent from application
                                                   • No manufacturing data                              single laboratory validation tissue                   fees; 27 percent from product fees; 26
                                                requirements—sponsor can address in                     residue method demonstration.                         percent from establishment fees; and 27
                                                meeting assay non-interference, but data                                                                      percent from sponsor fees.
                                                                                                        B. Inflation Adjuster and Workload
                                                submission is not required.                                                                                     Dated: October 20, 2017.
                                                   • All other information is referenced                Adjuster
                                                                                                                                                              Leslie Kux,
                                                to previous drug experience reports.                      The inflation adjuster will remain the
                                                                                                                                                              Associate Commissioner for Policy.
                                                   • Sponsor makes submission and it                    same as for ADUFA III.
                                                                                                          The workload adjustment will                        [FR Doc. 2017–23172 Filed 10–24–17; 8:45 am]
                                                includes: Representative (Blue Bird)
                                                labeling, Veterinary Feed Directive (if                 continue to be calculated per Center for              BILLING CODE 4164–01–P

                                                applicable).                                            Veterinary Medicine Program Policy
                                                   • Includes a request for categorical                 and Procedures Manual 1243.3022,
                                                                                                        except that, for purposes of calculating              DEPARTMENT OF HEALTH AND
                                                exclusion from the need to prepare an
                                                                                                        the workload adjustment, it has been                  HUMAN SERVICES
                                                environmental assessment (EA); i.e., no
                                                EA required.                                            agreed to reset the base years to fiscal              Food and Drug Administration
                                                   • Reference to presubmission                         year (FY) 2014 through FY 2018. There
                                                conference.                                             will be no workload adjustment for FY                 [Docket No. FDA–2016–D–2021]
                                                   • Right of reference (if applicable) to              2019. Workload adjustments are one-
                                                NADA(s) not owned by the filing                         time adjustments and are calculated                   Deciding When To Submit a 510(k) for
                                                sponsor of the ADAA combination                         annually.                                             a Software Change to an Existing
                                                medicated feed application has been                                                                           Device; Guidance for Industry and
                                                                                                        C. Offset Provision and Excess                        Food and Drug Administration Staff;
                                                received by the Agency.
                                                   The Agency will review and act on 90                 Collections                                           Availability
                                                percent of ADAA combination                                The proposal adds financial flexibility            AGENCY:    Food and Drug Administration,
                                                                                                        by eliminating the final year offset of
sradovich on DSK3GMQ082PROD with NOTICES




                                                medicated feed applications within 100                                                                        HHS.
                                                days for those applications accepted for                over collections provision and making                 ACTION:   Notice of availability.
                                                the 60-day timeframe and there is a                     any excess collections available to
                                                need for minor amendments.                              enhance the review process in real time.              SUMMARY:  The Food and Drug
                                                   If any of the above conditions cannot                The proposal provides authority for the               Administration (FDA or Agency) is
                                                be met, the ADAA combination                            Secretary of Health and Human Services                announcing the availability of the
                                                medicated feed application performance                  (the Secretary) when setting fees to                  guidance entitled ‘‘Deciding When to
                                                metric will be placed in the original                   reduce a calculated workload                          Submit a 510(k) for a Software Change


                                           VerDate Sep<11>2014   22:06 Oct 24, 2017   Jkt 244001   PO 00000   Frm 00072   Fmt 4703   Sfmt 4703   E:\FR\FM\25OCN1.SGM   25OCN1


                                                                          Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices                                           49383

                                                to an Existing Device.’’ FDA is issuing                 Staff, FDA will post your comment, as                 from the internet. See the
                                                this final guidance document to clarify                 well as any attachments, except for                   SUPPLEMENTARY INFORMATION      section for
                                                when a software change in a legally                     information submitted, marked and                     information on electronic access to the
                                                marketed medical device would require                   identified, as confidential, if submitted             guidance. Submit written requests for a
                                                that a manufacturer submit a premarket                  as detailed in ‘‘Instructions.’’                      single hard copy of the guidance
                                                notification (510(k)) to FDA. FDA is                       Instructions: All submissions received             document entitled ‘‘Deciding When to
                                                correcting an error in the docket number                must include the Docket No. FDA–                      Submit a 510(k) for a Software Change
                                                assigned to the ‘‘Deciding When to                      2016–D–2021 for ‘‘Deciding When to                    to an Existing Device’’ to the Office of
                                                Submit a 510(k) for a Software Change                   Submit a 510(k) for a Software Change                 the Center Director, Guidance and
                                                to an Existing Device’’ notice of                       to an Existing Device.’’ Received                     Policy Development, Center for Devices
                                                availability when it published in the                   comments will be placed in the docket                 and Radiological Health, Food and Drug
                                                Federal Register (81 FR 52441, August                   and, except for those submitted as                    Administration, 10903 New Hampshire
                                                8, 2016). The docket number currently                   ‘‘Confidential Submissions,’’ publicly                Ave., Bldg. 66, Rm. 5431, Silver Spring,
                                                is FDA–2011–D–0453. FDA is changing                     viewable at https://www.regulations.gov               MD 20993–0002, or the Office of
                                                the docket number to FDA–2016–D–                        or at the Dockets Management Staff                    Communication, Outreach, and
                                                2021. This action is administrative in                  between 9 a.m. and 4 p.m., Monday                     Development, Center for Biologics
                                                nature and is being taken to avoid any                  through Friday.                                       Evaluation and Research, Food and
                                                potential confusion in the docket.                         • Confidential Submissions—To                      Drug Administration, 10903 New
                                                                                                        submit a comment with confidential                    Hampshire Ave., Bldg. 71, Rm. 3128,
                                                DATES: The announcement of the
                                                                                                        information that you do not wish to be                Silver Spring, MD 20993–0002. Send
                                                guidance is published in the Federal
                                                                                                        made publicly available, submit your                  one self-addressed adhesive label to
                                                Register on October 25, 2017.                           comments only as a written/paper
                                                ADDRESSES: You may submit either
                                                                                                                                                              assist that office in processing your
                                                                                                        submission. You should submit two                     request.
                                                electronic or written comments on                       copies total. One copy will include the
                                                Agency guidances at any time as                         information you claim to be confidential              FOR FURTHER INFORMATION CONTACT:
                                                follows:                                                with a heading or cover note that states              Linda Ricci, Center for Devices and
                                                                                                        ‘‘THIS DOCUMENT CONTAINS                              Radiological Health, Food and Drug
                                                Electronic Submissions                                                                                        Administration, 10903 New Hampshire
                                                                                                        CONFIDENTIAL INFORMATION.’’ The
                                                  Submit electronic comments in the                     Agency will review this copy, including               Ave., Bldg. 66, Rm. G634, Silver Spring,
                                                following way:                                          the claimed confidential information, in              MD 20993–0002, 301–796–6325,
                                                  • Federal eRulemaking Portal:                         its consideration of comments. The                    linda.ricci@fda.hhs.gov; and Stephen
                                                https://www.regulations.gov. Follow the                 second copy, which will have the                      Ripley, Center for Biologics Evaluation
                                                instructions for submitting comments.                   claimed confidential information                      and Research, Food and Drug
                                                Comments submitted electronically,                      redacted/blacked out, will be available               Administration, 10903 New Hampshire
                                                including attachments, to https://                      for public viewing and posted on                      Ave., Bldg. 71, Rm. 7301, Silver Spring,
                                                www.regulations.gov will be posted to                   https://www.regulations.gov. Submit                   MD 20993–0002, 240–402–7911.
                                                the docket unchanged. Because your                      both copies to the Dockets Management                 SUPPLEMENTARY INFORMATION:
                                                comment will be made public, you are                    Staff. If you do not wish your name and
                                                solely responsible for ensuring that your                                                                     I. Background
                                                                                                        contact information to be made publicly
                                                comment does not include any                            available, you can provide this                          A 510(k) is required when a legally
                                                confidential information that you or a                  information on the cover sheet and not                marketed device subject to 510(k)
                                                third party may not wish to be posted,                  in the body of your comments and you                  requirements is about to be significantly
                                                such as medical information, your or                    must identify this information as                     changed or modified in design,
                                                anyone else’s Social Security number, or                ‘‘confidential.’’ Any information marked              components, method of manufacture, or
                                                confidential business information, such                 as ‘‘confidential’’ will not be disclosed             intended use. Significant changes or
                                                as a manufacturing process. Please note                 except in accordance with 21 CFR 10.20                modifications are those that could
                                                that if you include your name, contact                  and other applicable disclosure law. For              significantly affect the safety or
                                                information, or other information that                  more information about FDA’s posting                  effectiveness of the device, or major
                                                identifies you in the body of your                      of comments to public dockets, see 80                 changes or modifications in the
                                                comments, that information will be                      FR 56469, September 18, 2015, or access               intended use of the device
                                                posted on https://www.regulations.gov.                  the information at: https://www.gpo.gov/              (§ 807.81(a)(3) (21 CFR 807.81(a)(3)).
                                                  • If you want to submit a comment                     fdsys/pkg/FR-2015-09-18/pdf/2015-                     This guidance will aid manufacturers of
                                                with confidential information that you                  23389.pdf.                                            medical devices who intend to make a
                                                do not wish to be made available to the                    Docket: For access to the docket to                software modification to a 510(k)-
                                                public, submit the comment as a                         read background documents or the                      cleared device or other device subject to
                                                written/paper submission and in the                     electronic and written/paper comments                 510(k) requirements, such as a
                                                manner detailed (see ‘‘Written/Paper                    received, go to https://                              preamendments device or a device that
                                                Submissions’’ and ‘‘Instructions’’).                    www.regulations.gov and insert the                    was granted marketing authorization via
                                                                                                        docket number, found in brackets in the               the De Novo classification process
                                                Written/Paper Submissions                                                                                     under section 513(f)(2) of the Federal
                                                                                                        heading of this document, into the
                                                  Submit written/paper submissions as                   ‘‘Search’’ box and follow the prompts                 Food, Drug, and Cosmetic Act (the
                                                follows:                                                                                                      FD&C Act) (21 U.S.C. 360c(f)(2)) (also
sradovich on DSK3GMQ082PROD with NOTICES




                                                                                                        and/or go to the Dockets Management
                                                  • Mail/Hand delivery/Courier (for                     Staff, 5630 Fishers Lane, Rm. 1061,                   referred to together as ‘‘existing
                                                written/paper submissions): Dockets                     Rockville, MD 20852.                                  devices’’), during the process of
                                                Management Staff (HFA–305), Food and                       You may submit comments on any                     deciding whether the software
                                                Drug Administration, 5630 Fishers                       guidance at any time (see 21 CFR                      modification exceeds the regulatory
                                                Lane, Rm. 1061, Rockville, MD 20852.                    10.115(g)(5)).                                        threshold of § 807.81(a)(3) for
                                                  • For written/paper comments                             An electronic copy of the guidance                 submission and clearance of a new
                                                submitted to the Dockets Management                     document is available for download                    510(k).


                                           VerDate Sep<11>2014   22:06 Oct 24, 2017   Jkt 244001   PO 00000   Frm 00073   Fmt 4703   Sfmt 4703   E:\FR\FM\25OCN1.SGM   25OCN1


                                                49384                     Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices

                                                   This guidance specifically addresses                 II. Significance of Guidance                          through Friday; they are also available
                                                software design and technology                             This guidance is being issued                      electronically at https://
                                                modifications, including firmware. This                 consistent with FDA’s good guidance                   www.regulations.gov. FDA has verified
                                                guidance does not apply to software for                 practices regulation (21 CFR 10.115).                 the Web site addresses, as of the date
                                                which the Agency has stated in                          The guidance represents the current                   this document publishes in the Federal
                                                guidance that it does not intend to                     thinking of FDA on ‘‘Deciding When to                 Register, but Web sites are subject to
                                                enforce compliance with applicable                      Submit a 510(k) for a Software Change                 change over time.
                                                regulatory controls (e.g., ‘‘Mobile                     to an Existing Device.’’ It does not                  1. ‘‘The Least Burdensome Provisions of the
                                                Medical Applications: Guidance for                      establish any rights for any person and                     FDA Modernization Act of 1997:
                                                Industry and FDA Staff,’’ issued                        is not binding on FDA or the public.                        Concept and Principles,’’ dated October
                                                February 9, 2015, available on the                      You can use an alternative approach if                      4, 2002, available at: https://
                                                internet at https://www.fda.gov/                                                                                    www.fda.gov/downloads/Medical
                                                                                                        it satisfies the requirements of the
                                                downloads/medicaldevices/.../                                                                                       Devices/DeviceRegulationandGuidance/
                                                                                                        applicable statutes and regulations. This                   GuidanceDocuments/ucm085999.pdf.
                                                ucm263366.pdf) and software that does                   guidance is not subject to Executive                  2. ‘‘Suggested Format for Developing and
                                                not meet the definition of a medical                    Order 12866.                                                Responding to Deficiencies in
                                                device at section 201(h) of the FD&C Act                                                                            Accordance with the Least Burdensome
                                                (21 U.S.C. 321(h)).                                     III. Electronic Access
                                                                                                                                                                    Provisions of FDAMA,’’ dated November
                                                   In the Federal Register on August 8,                    Persons interested in obtaining a copy                   2, 2000, available at: https://
                                                2016, FDA announced the availability of                 of the guidance may do so by                                www.fda.gov/downloads/Medical
                                                the draft guidance and interested parties               downloading an electronic copy from                         Devices/DeviceRegulationandGuidance/
                                                were requested to comment by                            the internet. A search capability for all                   GuidanceDocuments/ucm073680.pdf.
                                                November 7, 2016. FDA considered                        Center for Devices and Radiological                     Dated: October 20, 2017.
                                                comments received on the draft                          Health guidance documents is available                Leslie Kux,
                                                guidance and revised the guidance as                    at https://www.fda.gov/MedicalDevices/                Associate Commissioner for Policy.
                                                appropriate.                                            DeviceRegulationandGuidance/                          [FR Doc. 2017–23196 Filed 10–24–17; 8:45 am]
                                                   This guidance is not intended to                     GuidanceDocuments/default.htm.
                                                                                                                                                              BILLING CODE 4164–01–P
                                                implement significant policy changes to                 Guidance documents are also available
                                                FDA’s current thinking on when                          at https://www.fda.gov/BiologicsBlood
                                                submission of a new 510(k) is required                  Vaccines/GuidanceCompliance                           DEPARTMENT OF HEALTH AND
                                                for a software change to an existing                    RegulatoryInformation/Guidances/                      HUMAN SERVICES
                                                device. Rather, the intent of this                      default.htm or https://
                                                guidance is to enhance the                              www.regulations.gov. Persons unable to                Office of the Secretary
                                                predictability, consistency, and                        download an electronic copy of
                                                transparency of the ‘‘when to submit’’                  ‘‘Deciding When to Submit a 510(k) for                Notice of Interest Rate on Overdue
                                                decision-making process by providing a                  a Software Change to an Existing                      Debts
                                                least burdensome approach, and                          Device’’ may send an email request to
                                                                                                                                                                 Section 30.18 of the Department of
                                                describing in greater detail the                        CDRH-Guidance@fda.hhs.gov to receive
                                                                                                                                                              Health and Human Services’ claims
                                                regulatory framework, policies, and                     an electronic copy of the document.
                                                                                                                                                              collection regulations (45 CFR part 30)
                                                practices underlying such a decision,                   Please use the document number
                                                                                                                                                              provides that the Secretary shall charge
                                                specifically as it relates to software                  1500055 to identify the guidance you
                                                                                                                                                              an annual rate of interest, which is
                                                changes. The recommendations                            are requesting.
                                                                                                                                                              determined and fixed by the Secretary
                                                discussed in this guidance for                          IV. Paperwork Reduction Act of 1995                   of the Treasury after considering private
                                                evaluating when a software change to an                   This guidance refers to previously                  consumer rates of interest on the date
                                                existing device would trigger the                       approved collections of information                   that the Department of Health and
                                                requirement that a manufacturer submit                  found in FDA regulations. These                       Human Services becomes entitled to
                                                a new 510(k) to the Agency are                          collections of information are subject to             recovery. The rate cannot be lower than
                                                consistent with the least burdensome                    review by the Office of Management and                the Department of Treasury’s current
                                                principles (Refs. 1 and 2). This guidance               Budget (OMB) under the Paperwork                      value of funds rate or the applicable rate
                                                applies the least burdensome principles,                Reduction Act of 1995 (44 U.S.C. 3501–                determined from the ‘‘Schedule of
                                                in part, by reliance on risk management                 3520). The collections of information in              Certified Interest Rates with Range of
                                                and the quality system regulation (21                   21 CFR part 820 are approved under                    Maturities’’ unless the Secretary waives
                                                CFR part 820) to determine whether                      OMB control number 0910–0073; the                     interest in whole or part, or a different
                                                submission of a new 510(k) is required                  collections of information in 21 CFR                  rate is prescribed by statute, contract, or
                                                for a software change to an existing                    part 807, subpart E are approved under                repayment agreement. The Secretary of
                                                device.                                                 OMB control number 0910–0120; the                     the Treasury may revise this rate
                                                   Elsewhere in this issue of the Federal               collections of information in 21 CFR                  quarterly. The Department of Health and
                                                Register, FDA is announcing the                         part 803 are approved under OMB                       Human Services publishes this rate in
                                                availability of the guidance document                   control number 0910–0437; and the                     the Federal Register.
                                                entitled ‘‘Deciding When to Submit a                    collections of information in 21 CFR                     The current rate of 93⁄4%, as fixed by
                                                510(k) for a Change to an Existing                      parts 801 are approved under OMB                      the Secretary of the Treasury, is certified
                                                Device,’’ to aid manufacturers of                                                                             for the quarter ended September 30,
sradovich on DSK3GMQ082PROD with NOTICES




                                                                                                        control number 0910–0485.
                                                medical devices who intend to make                                                                            2017. This rate is based on the Interest
                                                non-software changes to an existing                     V. References                                         Rates for Specific Legislation, ‘‘National
                                                device during the process of deciding                     The following references are on                     Health Services Corps Scholarship
                                                whether the modification exceeds the                    display in the Dockets Management                     Program (42 U.S.C. 254o(b)(1)(A))’’ and
                                                regulatory threshold of § 807.81(a)(3) for              Staff (see ADDRESSES) and are available               ‘‘National Research Service Award
                                                submission and clearance of a new                       for viewing by interested persons                     Program (42 U.S.C. 288(c)(4)(B)).’’ This
                                                510(k).                                                 between 9 a.m. and 4 p.m., Monday                     interest rate will be applied to overdue


                                           VerDate Sep<11>2014   22:06 Oct 24, 2017   Jkt 244001   PO 00000   Frm 00074   Fmt 4703   Sfmt 4703   E:\FR\FM\25OCN1.SGM   25OCN1



Document Created: 2017-10-25 01:17:02
Document Modified: 2017-10-25 01:17:02
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of availability.
DatesThe announcement of the guidance is published in the Federal Register on October 25, 2017.
ContactLinda Ricci, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. G634, Silver Spring, MD 20993-0002, 301-796-6325, [email protected]; and Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240- 402-7911.
FR Citation82 FR 49382 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR